Reverse Splits

[sludgehound]

AEMD to do 1-50 to get Nasdaq? 0.195 now

07:14 AM EDT, 04/08/2015 (MT Newswires) -- Aethlon Medical (AEMD), which is developing targeted therapeutic devices to address infectious diseases and cancer, said it will implement a 1-for-50 reverse stock split in preparation for a possible Nasdaq listing.
The split is subject to approval by the Financial Industry Regulatory Authority (FINRA), which is expected on April 10, 2015. The reverse split will reduce the number of shares of the Company's common stock outstanding from approximately 323 million to approximately 6.7 million.
Directors approved the stock split in part to support the Nasdaq Capital Market listing application. At present, the company does not meet all of the initial listing requirements for the exchange and cannot be assured the application will be approved.
The stock closed on the OTC markets at $0.25 on Tuesday.
Price: 0.25, Change: , Percent Change: